Early Phase Services
More of What You Need for a Stronger Start in Phase I
Your journey from new molecule to new medicine starts with appropriate subjects, world class facilities, and more timely results. PAREXEL provides comprehensive early phase testing services through our own hospital-based clinical units on three continents. This ensures the highest patient safety standards, on-site lab facilities, and quick, in-house access to all of the healthy volunteers and diverse patient populations you need through our global patient database.
We can even perform your Phase I trials across multiple locations at once, thanks to our harmonized Standardized Operating Procedures and integrated, Software-as-a-Service (SaaS)-based technologies that expedite vital decision-making in real time, wherever you need us to be, worldwide. All to get you faster results and more accurate, useful data from First-in-Human through Proof-of-Concept, so your team has the information it needs sooner to continue with the next part of your journey.
Phase I, First-in-Human
With participants safety paramount, PAREXEL® Early Phase has developed a superior range of services for the conduct of first-in-man - or First-in-Human (FiH) - and other Phase I safety studies, giving you the assurance that your compound will move into...
Clinical PK/PD and Pharmacometrics Services
The attrition rate in the pharmaceutical industry remains high, with a Phase III failure rate of 40-50%. To address this issue, there is now a larger emphasis on quantitative predictions and translational science from the early exploratory stage...
PAREXEL® Early Phase are world leaders in the performance of ethnobridging clinical trials. As inclusion of Asian countries in global drug development strategies and registration of drugs in the Asia Pacific region has become increasingly important in recent years...
Bioanalytical and Biomarkers
Bioanalysis is the discipline that allows quantitative determination of chemical entities and biomarkers in biological matrices. PAREXEL® Early Phase offers the highest quality bioanalytical services for qualitative and quantitative drug, metabolite, and biomarker analysis in a variety of matrices.
Positioning Emerging BioPharma for Investors
Download our new report, "Positioning Emerging BioPharma for Investors," essential criteria biopharmaceutical investors seek when evaluating compounds and companies.
Starting Stronger in Phase I Through IIA
Adding value from first-in-human through proof-of-concept.Achieve success through early testing of compounds in patients and healthy volunteers. Read more.
The Changing Face of the Early Phase Volunteer
Download a copy of the March 17th Executive Insight article, "The Changing Face of the Early Phase Volunteer," written by Thomas Senderovitz, M.D., Senior Vice President, Clinical Research Services, PAREXEL and Sy Pretorius, M.D., Corporate Vice President & Worldwide Head Early Phase, PAREXEL.